Work

SP31 Phase 1b study of the safety, tolerability, pharmacokinetics, immunogenicity, and efficacy of adimanebart in participants with DOK7-CMS

Year: 2026

Type: conference-abstract

Source: Neuromuscular Disorders

DOI: 10.1016/j.nmd.2026.107154

Authors: Hanns Lochmüller, Lorenzo Maggi, Nancy L. Kuntz, Steven J. Burden, Tonke van Bragt, Mitsunori Watanabe, Stéphanie Dincq, Willem Talloen, Jamie Lim, Hege Michiels, Sonya Patel, Syed Raza, Kate Lyden, Ieuan Clay, Yaya Zhai, Robert T. Marcotte, Roeland Vanhauwaert, Rebecca Shilling, Jacqueline Palace

Language: English

Topic: Neurogenetic and Muscular Disorders Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7214782849

Cites:

Cited by:

Related to: 10